STRATEGIC NEWS WATCH — August 18, 2026
|
Amylyx’s avexitide hit its Phase 3 endpoint in post-bariatric hypoglycemia with a 55% reduction in severe events, clearing a path to becoming the first approved therapy for a condition that currently has no pharmacologic options. Today’s top developments:
|
What to Watch
- Amylyx regulatory filing — With avexitide’s pivotal data in hand and no approved therapy for post-bariatric hypoglycemia, look for NDA-submission timing and any breakthrough or priority-review signals that could speed a first-in-class path.
- Regeneron’s capital deployment — Another late-stage setback atop a roughly $18B cash pile sharpens analyst pressure for a sizable acquisition; the open question is whether Regeneron shifts from bolt-ons to a franchise-scale deal.
- Rare-disease deal velocity — Two rare-disease transactions in a single session point to sustained premiums for late-stage, near-approval assets; valuations will reveal whether mid-caps keep outbidding for clean clinical profiles.
- Hims & Hers vs. FTC — The compounded-GLP-1 fight is a bellwether for telehealth prescribing; expect preliminary-injunction proceedings and early signs of whether rival platforms adjust their offerings.
- CAR-T site-of-care economics — REMS removal opens community oncology to cell therapy; track how the big-three drug wholesalers position for cold-chain distribution as delivery decentralizes.
This brief highlights the edition’s top stories. Read the full August 18, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.